The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

Cancer Research

Volumn 69, Issue 1, 2009, Pages 161-170

  Huang, Fei ^a   Greer, Ann ^a   Hurlburt, Warren ^a   Han, Xia ^a   Hafezi, Rameh ^a   Wittenberg, Gayle M ^a,c   Reeves, Karen ^a   Chen, Jiwen ^a   Robinson, Douglas ^a   Li, Aixin ^a   Lee, Francis Y ^a   Gottardis, Marco M ^a   Clark, Edwin ^a   Helman, Lee ^b   Attar, Ricardo M ^a,d   Dongre, Ashok ^a   Carboni, Joan M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SIEMENS CORPORATE RESEARCH   (United States)

^d Oncology Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BMS 536924; BMS 690514; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; DNA FINGERPRINTING; DRUG EFFICACY; DRUG POTENCY; EWING SARCOMA; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SARCOMA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZIMIDAZOLES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; NEUROBLASTOMA; PYRIDONES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; SARCOMA;

EID: 58249101005     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0835     Document Type: Article

References (50)

1. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
2. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44.
3. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
4. Baserga R, Peruzzi F, Reiss K. The IGF-I receptor in cancer biology. Int J Cancer 2003;107:873-7.
5. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12.
6. Hartog H, Wesseling J, Boezen HM, van der Graaf WT. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007;43:1895-904.
7. Merlino G, Helman LJ. Rhabdomyosarcoma working out the pathways. Oncogene 1999;18:5340-8.
8. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4.
9. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-II in primary and metastatic osteosarcoma. J Surg Oncol 1998;69:21-7.
10. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-II are expressed in primary human sarcomas. Cancer Res 1995;55:129-34.
11. Benini S, Manara MC, Baldini N, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001;7:1790-7.
12. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76.
13. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13:1322-30.
14. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007;106:39-47.
15. Storz P, Döppler H, Pfizenmaier K, Müller G. Insulin selectively activates STAT5b, but not STAT5a, via a JAK2-independent signalling pathway in Kym-1 rhabdomyosarcoma cells. FEBS Lett 1999;464:159-63.
16. Morrione A, Valentinis B, Xu SQ, et al. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci U S A 1997;94:3777-82.
17. Zhang H, Pelzer AM, Kiang DT, Yee D. Downregulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7.
18. Wittman M, Carboni J, Attar R, et al. Discovery of a (1H-benzoimidazol-2- yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 2005;48:5639-43.
19. Baselga J, Tripathy D, Mendelsohn, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 2005;14:737-44.
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
21. Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422-31.
22. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
23. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300.
24. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38.
25. Tallarida RJ. Drug Synergism and Dose-Effect Data Analysis. 1st ed. Chapman & Hall/CRC; 2000.
26. Anderle M, Roy S, Lin H, Becker C, Joh o K. Quantifying reproducibility for differential proteomics: noise analysis for protein liquid chromatography-mass spectrometry of human serum. Bioinformatics 2004;20:3575-82.
27. Fanyu MF, Wiener MC, Sachs JR, et al. Quantitative analysis of complex peptide mixtures using FTMS and differential mass spectrometry. J Am Soc Mass Spectrom 2007;18:226-33.
28. Eng JK, McCormack AL, Yates JR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994;5:976-89.
29. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
30. Haluska P, Carboni JM, TenEyck C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7:2589-98.
31. Claussen M, Kübler B, Wendland M, et al. Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by cathepsin D. Endocrinology 1997;138:3797-803.
32. Ebadi M, Iversen PL. Metallothionein in carcinogenesis and cancer chemotherapy. Gen Pharmacol 1994;25:1297-310.
33. Gavai A, Chen P, Norris D, et al. Structure activity relationships for 5-substituted pyrrolo(2,1-f )(1,2,4)triazine-based inhibitors of pan-HER/VEGFR2 kinases: identification of the clinical candidate. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; Apr 14-18, 2007; Abstract #4170.
34. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007;25:3002.
35. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1991;359:162-5.
36. Hahm, KB, Cecile Lee KC, Im YH, et al. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999;23:222-7.
37. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83.
38. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
39. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 2007;13:1438-44.
40. Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res 2006;16:224-39.
41. Osmak M, Svetic B, Gabrijelcic-Geiger D, Skrk J. Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B. Anticancer Res 2001;21:481-3.
42. Zheng X, Chou PM, Mirkin BL, Rebbaa A. Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res 2004;64:1773-80.
43. Brennan D, Hu Y, Joubeh S, et al. Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. J Cell Sci 2007;120:758-71.
44. Rath GM, Schneider C, Dedieu S, et al. The Cterminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim Biophys Acta 2006;1763:1125-34.
45. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs 2002;13:S3-10.
46. Mahadevan D, Cooke L, Riley C, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26:3909-19.
47. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
48. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005;7:R570-9.
49. Steinbach JP , Eisenmann C, Klumpp A, Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun 2004;321:524-30.
50. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999;56:1-10.